Glycoprotein IIB/IIIA inhibitor

Revision as of 01:22, 22 October 2020 by ClaireLewis (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


  • By competing with fibrinogen and von Willebrand factor (vWF) for GP IIb/IIIa binding, GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived thrombus formation
  • Mostly indicated for patients undergoing PCI for ACS

Glycoprotein IIB/IIIA inhibitors